1q21.1 microduplication syndrome

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:250994OMIM:612475Q92.3
Who is this for?
Show terms as
2Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

1q21.1 microduplication syndrome (also known as 1q21.1 duplication syndrome or chromosome 1q21.1 duplication syndrome) is a rare chromosomal disorder caused by a small duplication of genetic material on the long arm of chromosome 1 at position 21.1. This region contains several genes, and the extra copy of these genes is thought to disrupt normal development, though the exact mechanisms are not fully understood. The condition is characterized by variable expressivity and incomplete penetrance, meaning that individuals carrying the duplication may have a wide range of symptoms or, in some cases, no apparent clinical features at all. The syndrome primarily affects the neurological, musculoskeletal, and craniofacial systems. Key clinical features include mild to moderate intellectual disability, developmental delay (particularly speech and language delay), autism spectrum disorder, and other behavioral or psychiatric manifestations such as attention deficit hyperactivity disorder (ADHD) and anxiety. Macrocephaly (abnormally large head size) is a frequently reported feature. Some individuals may present with mild dysmorphic facial features, though these are often subtle and nonspecific. Congenital heart defects have been reported in a subset of patients. Hypotonia (reduced muscle tone) in infancy and joint hypermobility may also occur. Growth parameters can be variable, with some individuals showing tall stature. There is currently no cure or specific targeted therapy for 1q21.1 microduplication syndrome. Management is symptomatic and supportive, tailored to each individual's clinical presentation. This may include early intervention programs, speech and occupational therapy, behavioral therapy, special educational support, and appropriate management of any cardiac or other organ-specific anomalies. Psychiatric symptoms may be managed with standard pharmacological and behavioral approaches. Genetic counseling is recommended for affected individuals and their families, as the duplication may be inherited from a mildly affected or apparently unaffected parent.

Also known as:

Clinical phenotype terms— hover any for plain English:

Inheritance

Autosomal dominant

Passed on from just one parent; each child has about a 50% chance of inheriting it

Age of Onset

Variable

Can begin at different ages, from infancy through adulthood

Orphanet ↗OMIM ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for 1q21.1 microduplication syndrome.

View clinical trials →

No actively recruiting trials found for 1q21.1 microduplication syndrome at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the 1q21.1 microduplication syndrome community →

Specialists

2 foundView all specialists →

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to 1q21.1 microduplication syndrome.

Search all travel grants →NORD Financial Assistance ↗

Community

Open 1q21.1 microduplication syndromeForum →

No community posts yet. Be the first to share your experience with 1q21.1 microduplication syndrome.

Start the conversation →

Latest news about 1q21.1 microduplication syndrome

No recent news articles for 1q21.1 microduplication syndrome.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about 1q21.1 microduplication syndrome

What is 1q21.1 microduplication syndrome?

1q21.1 microduplication syndrome (also known as 1q21.1 duplication syndrome or chromosome 1q21.1 duplication syndrome) is a rare chromosomal disorder caused by a small duplication of genetic material on the long arm of chromosome 1 at position 21.1. This region contains several genes, and the extra copy of these genes is thought to disrupt normal development, though the exact mechanisms are not fully understood. The condition is characterized by variable expressivity and incomplete penetrance, meaning that individuals carrying the duplication may have a wide range of symptoms or, in some cases

How is 1q21.1 microduplication syndrome inherited?

1q21.1 microduplication syndrome follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

Which specialists treat 1q21.1 microduplication syndrome?

2 specialists and care centers treating 1q21.1 microduplication syndrome are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.